OpenBilldrug price receipt

NADAC week of 2026-10-14

BEVESPI AEROSPHERE INHALER

FDA nonproprietary name: glycopyrrolate and formoterol fumarate

For 1 g

Pharmacies pay

$40.86 filed

1 × $40.85993 per GM

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$38.54 filed

1 × $38.53721 per GM, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

0.94× estimated

Medicare paid 6% less than pharmacies pay.

Part D averages every strength and form sold under “Bevespi Aerosphere” / “Glycopyrrolate/Formoterol Fum” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$51.99 estimated

$40.86 + $6.13 (15%) + $5.00 fee per fill = $51.99

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

BEVESPI AEROSPHERE INHALER is how the CMS NADAC file names this product. The FDA NDC Directory lists it as glycopyrrolate and formoterol fumarate, under the trade name “BEVESPI AEROSPHERE”.

FDA gives its dosage form as aerosol, metered and its route as respiratory (inhalation).

The labeler, the company named on the label, is AstraZeneca Pharmaceuticals LP.

FDA lists it under 3 Established Pharmacologic Classes: Anticholinergic, beta2-Adrenergic Agonist and Cholinergic Muscarinic Antagonist.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 00310-4600-12.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $40.86 for 1 g (1 × $40.85993 per GM, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

The NDC

Compared with its class

Its NADAC price is $40.85993 per GM filed.

Of the 7 other products in FDA’s Anticholinergic class priced per GM, 5 have a higher middle NADAC price and 2 a lower one. The one in the middle is STIOLTO RESPIMAT INHALER (60), at $115.80015 per GM filed (eff. 2026-09-23).

Of the 24 other products in FDA’s beta2-Adrenergic Agonist class priced per GM, 5 have a higher middle NADAC price and 19 a lower one. The one in the middle is FLUTICASONE-SALMETEROL 115-21, at $20.70767 per GM filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $38.54 for 1 g, at an average of $38.53721 per GM in 2024 (2024-01-01 to 2024-12-31) for “Bevespi Aerosphere” and “Glycopyrrolate/Formoterol Fum”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 125,109 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for BEVESPI AEROSPHERE INHALER labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Bevespi Aerosphere / Glycopyrrolate/Formoterol Fum: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's GM. Joined on brand name.
Why does this page start at 1 g?
The FDA package description of NDC 00310-4600-12 (“120 AEROSOL, METERED in 1 INHALER (0310-4600-12)”) does not give one amount in g, NADAC’s unit for this product. So the card starts at 1 GM; change it to match your prescription.